CHAPEL HILL, N.C., Oct. 31, 2024 (GLOBE NEWSWIRE) — Tenax Therapeutics, Inc. (Nasdaq: TENX), a Part 3, development-stage pharmaceutical firm centered on figuring out, creating and commercializing merchandise that deal with cardiovascular and pulmonary illnesses with excessive unmet medical want, as we speak introduced that it’s going to take part within the Guggenheim Healthcare Innovation Convention in Boston, Massachusetts, from November 11-13, 2024. Tenax’s CEO, Chris Giordano, will present an replace on the corporate and the continuing improvement of levosimendan, in a session buyers can attend reside or through webcast.
Format: Fireplace Chat
Presenter: Chris Giordano, President & Chief Govt Officer
Date and time: November 13, 2024 at 1:00 PM EST
Webcast: https://wsw.com/webcast/guggen/tenx/1967811
The reside and archived webcast of the presentation will probably be accessible from the Firm’s investor relations webpage.
About Tenax Therapeutics
Tenax Therapeutics, Inc. is a Part 3, development-stage pharmaceutical firm centered on figuring out, creating, and commercializing merchandise that deal with cardiovascular and pulmonary illnesses with excessive unmet medical want. The Firm owns world rights to develop and commercialize I.V., subcutaneous, and oral formulations of levosimendan. Tenax is also creating a novel oral formulation of imatinib. For extra data, go to www.tenaxthera.com. Tenax’s widespread inventory is listed on The Nasdaq Inventory Market LLC underneath the image TENX.
Contacts
Investor Contact:
John Fraunces
Managing Director
LifeSci Advisors, LLC
C: 917-355-2395, or
Brian Mullen (NASDAQ:)
LifeSci Advisors, LLC
C: 203-461-1175
Supply: Tenax Therapeutics
